Home

Sponzorský dar Ale George Bernard teva laquinimod 2017 Vyloučit Moderátor kůže

Frontiers | Laquinimod Inhibits Inflammation-Induced Angiogenesis in the Cornea | Medicine
Frontiers | Laquinimod Inhibits Inflammation-Induced Angiogenesis in the Cornea | Medicine

Teva drops laquinimod for most common form of MS after failed trial - PMLiVE
Teva drops laquinimod for most common form of MS after failed trial - PMLiVE

Laquinimod treatment in the R6/2 mouse model | Scientific Reports
Laquinimod treatment in the R6/2 mouse model | Scientific Reports

425
425

Teva Pharmaceuticals - Wikiwand
Teva Pharmaceuticals - Wikiwand

Teva Archives - Pharmaceutical Technology
Teva Archives - Pharmaceutical Technology

MS Therapy Laquinimod Fails to Meet Key Trial Goal of Slowing the Disease
MS Therapy Laquinimod Fails to Meet Key Trial Goal of Slowing the Disease

Teva May Have to Make Difficult Capital Allocation Decisions Under Pressure From Potential Generic Competition, Deleveraging Goals - Reorg
Teva May Have to Make Difficult Capital Allocation Decisions Under Pressure From Potential Generic Competition, Deleveraging Goals - Reorg

Teva and MedinCell Announce Positive Results for Registration Trial of Investigational Extended-Release Subcutaneous Injectable Risperidone for Patients with Schizophrenia | Business Wire
Teva and MedinCell Announce Positive Results for Registration Trial of Investigational Extended-Release Subcutaneous Injectable Risperidone for Patients with Schizophrenia | Business Wire

425
425

Safety and in vivo immune assessment of escalating doses of oral laquinimod in patients with RRMS | Journal of Neuroinflammation | Full Text
Safety and in vivo immune assessment of escalating doses of oral laquinimod in patients with RRMS | Journal of Neuroinflammation | Full Text

TEVA Annual Report 2014 | PDF | Food And Drug Administration | Dividend
TEVA Annual Report 2014 | PDF | Food And Drug Administration | Dividend

Laquinimod - an overview | ScienceDirect Topics
Laquinimod - an overview | ScienceDirect Topics

A randomized, placebo-controlled, phase 2 trial of laquinimod in primary progressive multiple sclerosis | Neurology
A randomized, placebo-controlled, phase 2 trial of laquinimod in primary progressive multiple sclerosis | Neurology

Teva Terminates TV-45070 Development Agreement with Xenon
Teva Terminates TV-45070 Development Agreement with Xenon

PPMS Experimental Therapy Laquinimod Fails to Slow Brain Atrophy, Disease Progression
PPMS Experimental Therapy Laquinimod Fails to Slow Brain Atrophy, Disease Progression

Potential Huntington's Therapy Laquinimod Fails Primary Objective in Phase 2 Trial
Potential Huntington's Therapy Laquinimod Fails Primary Objective in Phase 2 Trial

Teva returns laquinimod global rights to Active Biotech
Teva returns laquinimod global rights to Active Biotech

Patient enrollment in Phase III trial of laquinimod completed
Patient enrollment in Phase III trial of laquinimod completed

Multiple Sclerosis: KOL Insight [2017]
Multiple Sclerosis: KOL Insight [2017]

Meet the Compound: Laquinimod – HD Insights
Meet the Compound: Laquinimod – HD Insights

Multiple Sclerosis Clinical Trial Update: Laquinimod
Multiple Sclerosis Clinical Trial Update: Laquinimod

Is Teva late reporting EU clinical trials?
Is Teva late reporting EU clinical trials?

Teva and Active Biotech Announce CONCERTO trial of Laquinimod trial fails
Teva and Active Biotech Announce CONCERTO trial of Laquinimod trial fails

MS Therapy Laquinimod Fails to Meet Key Trial Goal of Slowing the Disease
MS Therapy Laquinimod Fails to Meet Key Trial Goal of Slowing the Disease